Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2009.

At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million which were paid subsequent to September 30, 2009.

The net income for the third quarter ended September 30, 2009, was $0.6 million, or $0.01 per diluted share, compared to a net loss of $6.8 million, or $0.15 per diluted share, for the third quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement, a $1.4 million decrease in other selling, general and administrative expenses, and a $1.4 million decrease in non-cash compensation expense related to equity grants.

The net income for the nine months ended September 30, 2009, was $15.1 million, or $0.31 per diluted share, compared to a net loss of $49.1 million, or $1.11 per diluted share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and developm
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... -- Moms are ready to live the "measured life" ... kids, according to the results of the BabyCenter® U.S. ... for Moms, the latest installment in BabyCenter,s 21 st ... and parenting web and mobile destination worldwide, conducted the ... say they can,t think of a reason not to ...
(Date:10/22/2014)... Oregon , October 22, 2014 ... "Global Disposable Gloves Market (Product type, Form, End user, ... Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... global disposable gloves market. Based on key trends tracked, ... be valued at $7.9 billion by 2020, registering a ...
(Date:10/22/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... focused on the development of oral drug delivery ... its Phase IIa clinical trial of ORMD-0801, the ... 1 diabetes. The trial was conducted in ... Food and Drug Administration (FDA) Investigational New Drug ...
Breaking Medicine Technology:BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
...  Brainlab, a leader in software-driven medical technology, announced today ... at the University of California San Francisco (UCSF) Medical ... advanced neurosurgery procedures to help detect and remove brain ... is one of the top hospitals in the nation ...
... 2012  Lilly Diabetes and Walgreens are educating people ... common and misunderstood consequences of diabetes: hypoglycemia (low ... campaign at 43 Walgreens pharmacies throughout the Indianapolis ... about hypoglycemia that pharmacists may use when counseling ...
Cached Medicine Technology:UCSF Medical Center Treats Patients with New Brainlab Curve™ Image Guided Surgery 2UCSF Medical Center Treats Patients with New Brainlab Curve™ Image Guided Surgery 3Lilly Diabetes and Walgreens Launch Diabetes Hypoglycemia Awareness Campaign 2Lilly Diabetes and Walgreens Launch Diabetes Hypoglycemia Awareness Campaign 3
(Date:10/25/2014)... Background: , In 1998 Bob Savage founded ... pioneer in the field of establishing recovery community organizations. ... and when he retired, he set out to answer a ... , 1. Where are the people in ... , 2. Can the recovery community be organized to advocate ...
(Date:10/25/2014)... 25, 2014 QueenBeeTickets.com has a variety ... selection at affordable prices. Bob Seger & The Silver ... and Nationwide Arena are going on sale October 25 ... Here to browse the selection of tickets for ... , The famous singer is touring North America beginning ...
(Date:10/25/2014)... CT (PRWEB) October 25, 2014 Limbkeepers® ... upcoming episode of Innovations with Ed Begley Jr, airing ... times TBA. , In this episode, Innovations will focus ... helping to protect fragile, thinning skin on arms, hands, ... will learn about these versatile products, which help reduce ...
(Date:10/25/2014)... -- Researchers who discovered antibiotics in farmed and ... concern. The use of antibiotics in animals, ... contribute to the development of antibiotic-resistant bacteria that ... the study. Each year in the United ... and kill about 23,000, according to the Infectious ...
(Date:10/25/2014)... (HealthDay News) -- October,s shorter, darker days can trigger ... according to an expert. People affected by ... tired, lack motivation and even have trouble getting out ... suicide, said Dr. Angelos Halaris, a professor in the ... Chicago Stitch School of Medicine. "Seasonal affective disorder ...
Breaking Medicine News(10 mins):Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Pediatric Dengue Vaccine Initiative (PDVI), a program of the ... announced today their partnership to help develop and make ... of Dengue fever, the second most widespread tropical disease ... to which over 2 billion people are exposed and ...
... scientists at Dartmouth Medical School and Dartmouth College, have ... changing muscle metabolism and performance. // The researchers are ... of muscle diseases. , ,The researchers ... (or AMPK) is responsible for realizing the best muscle ...
... While kidney failure is a serious condition that ... these patients are prone to developing another grave ... Fibrosing Dermopathy (NSF/NFD). // First recognized as a ... or tightening of the skin, resulting in pain, ...
... after menopause, a change thought to be due, in part, ... // ,Now, research from the University of Michigan ... certain memory functions. In a study in the new issue ... that a group of postmenopausal women showed more brain activity ...
... who are overweight or obese have increased blood pressure ... risk of kidney damage previously found in this group ... at the American Society of Nephrology's 39th Annual Meeting ... demonstrated that filtration pressure in the kidney was higher ...
... two animal caretakers sent letters to city, state and federal ... not stringent //enough in treating waste from animals that died ... disease before it was sent to the city's sewage treatment ... request of the federal and city officials to study the ...
Cached Medicine News:Health News:Pediatric Dengue Vaccine Initiative and Hawaii Biotech Partner Against Dengue Fever 2Health News:Dartmouth researchers zero-in on a gene that heightens muscle performance 2Health News:Dermatologists Provide Unique Evidence of Possible Cause of Rare Skin Condition 2Health News:Hormone Therapy May Improve the Trip Down Memory Lane 2Health News:Kidney Blood Flow May Explain Increased Long-Term Risks for Obese Kidney Donors 2Health News:Complaints Against US Federal lab Over-ruled by Panel 2
Lead filled and faced bone mallet used to exert force on osteotomes, chisels, and gouges....
Straight curette with hollow handle and round cup....
Coarse rasp....
Rasp with down cutting pattern....
Medicine Products: